key: cord-0690445-8ekp6qfn
authors: Petrone, Linda; Picchianti-Diamanti, Andrea; Sebastiani, Gian Domenico; Aiello, Alessandra; Laganà, Bruno; Cuzzi, Gilda; Vanini, Valentina; Gualano, Gina; Grifoni, Alba; Ferraioli, Mario; Castilletti, Concetta; Meschi, Silvia; Vaia, Francesco; Nicastri, Emanuele; Sette, Alessandro; Goletti, Delia
title: Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with Immune Mediated Inflammatory Diseases
date: 2022-04-22
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2022.04.027
sha: 1cf91b9ddb93845cf380f448ccdea0db27be6875
doc_id: 690445
cord_uid: 8ekp6qfn

Objectives. We assessed vaccination-induced antibody and cellular responses against spike from the ancestral strain and from the delta (δ) SARS-CoV-2 variant in patients with Immune Mediated Inflammatory Diseases (IMID) on immunosuppressive therapy in comparison with immunocompetent subjects. Methods. We enrolled IMID patients and immunocompetent subjects having completed the vaccination schedule within 4-6 months from the first dose. The Interferon (IFN)-γ-response to spike peptides derived from the ancestral and the δ SARS-CoV-2 were measured by ELISA. Anti-RBD IgG antibodies were also evaluated. Results. We enrolled 43 IMID patients and 9 immunocompetent subjects. No significant differences were found comparing the specific immune response (IFN-γ) between IMID patients and immunocompetent subjects to the ancestral (p=0.36) or delta peptide pool (p=0.51). Nevertheless, IFN-γ-specific response to the ancestral or to the δ pools was reduced in subjects taking CTLA4-IgG or TNF-α inhibitors compared to subjects treated with IL-6 inhibitors or DMARDs. Regarding the antibody response, no significant differences were observed between IMID and immunocompetent individuals. Conclusions. Cellular responses to δ SARS-CoV-2 variant remain largely intact in IMID patients. However, the magnitude of these responses are dependent on the specific IMID immune suppressive regimen. Serological response was also similar among the IMID and control groups.

1. Cellular response to δ SARS-CoV-2 variant is present in IMID vaccinated patients 2. Cellular response magnitude to δ SARS-CoV-2 variant depend on the type of therapy 3. Serological response was similar among the IMID patients and control group

The World Health Organization (WHO) identified as variants of concern (VOC) all the viral variants with increased potential to spread or capacity to evade the natural or the vaccine-induced protection. The SARS-CoV-2 VOC are the α, β, γ and δ (WHO, 2021) ; moreover, very recently the omicron VOC has been recognized (Viana et al., 2022) . At the time of writing this report, the δ, with 41.4% of sequences identified (WHO, 2022) , was still a high spread VOC worldwide, and was associated to an exponential increase of infections and deaths (Cherian et al., 2021; Depres et al., 2021) due to its capacity to infect people with a viral load up to one thousand fold compared to the original strain (Campbell et al., 2021) . Indeed, several studies evaluated the ability of these VOC to bypass the protection induced by the natural infection or by vaccines (Pullian et al., 2022; Edara et al., 2021) , which are based on the ancestral SARS-CoV-2 strain. In particular, the rate of prevention against δ variant is reduced (Lopez Bernal et al., 2021a) although the protection against severe disease and death is still maintained after a complete vaccination (Lopez Bernal et al., 2021b) , indicating the importance of carrying out the vaccination schedule in the context of high circulation of δ variant.

T cell specific immunity is important for controlling infection. In particular, a coordinated immune response is crucial in COVID-19 (Sette and Crotty, 2021) and is pivotal for clearance of the virus and for the subsequent induction of B cell response (Sette and Crotty, 2021; Aiello et al., 2021; Cantini et al., 2021; Goletti et al., 2021) .

Immune Mediated Inflammatory Diseases (IMID) are associated to increased risk of hospitalization and death from COVID-19 (Belleudi et al., 2021) . Therefore, people suffering these diseases are considered as a priority target group for COVID-19 vaccine campaign (Picchianti-Diamanti et al., 2021) . Recently, we and others demonstrated that mRNA vaccines induce an immune response, both humoral and T-cell response, in patients with rheumatoid arthritis (RA) (Picchianti-Diamanti et al., 2021; Connolly et al., 2021; Deepak et al., 2021; Jyssum et al., 2021) . However, the magnitude of the response depends on the immunosuppressive therapy. In particular, the lowest T-cell viral specific response was observed in IMID patients under therapy with Cytotoxic T-Lymphocyte Antigen (CTLA) 4-IgG, Tumor Necrosis Factor (TNF)-α or Interleukin (IL)-6 inhibitors (Picchianti-Diamanti et al., 2021) .

Few evidences are available on the impact of VOCs on the vaccine-induced T-cell response in vulnerable populations. The comparison of the Interferon (IFN)-γsecreting T cells specific for the ancestral spike and VOC induced by a SARS-CoV-2 inactivated vaccine or by mRNA vaccine showed no differences in healthy subjects (Melo-González et al., 2021; Cassaniti et al., 2021) . Recently, a study evaluated the T-cell response against the ancestral viral strain and against α, β, γ viral variants in subjects on immunosuppressive therapy including patients with chronic inflammatory diseases (Collier et al., 2021) , demonstrating a reduction of the cellular response against viral variants particularly in individuals on triple immunosuppressive therapy.

However, the impact of the most spread δ variant has never been evaluated in patients with IMID. Therefore, in this study, we assessed the cellular response against δ SARS-CoV-2 variant following COVID-19 vaccination in IMID patients on immunosuppressive therapy in comparison with the results from immunocompetent subjects. The vaccine-induced antibody response was also evaluated.

Patients with IMID were enrolled at Sant'Andrea University Hospital in Rome (Picchianti-Diamanti et al., 2021) . Immunocompetent subjects have been described also in a recent study (Petrone et al., 2022) . Written informed consent was required to consecutively enroll immunocompetent and IMID subjects; clinical and demographic info were recorded at enrollment.

Two different spike SARS-CoV-2 peptide pools were used: the "ancestral" peptide pool, designed and carried out on the Wuhan-Hu-1 strain (GenBank ID:MN908947) and the "δ" peptide pool, designed and carried out on the GISAID ID:

EPI_ISL_2020950. Ancestral and δ peptide pools consisted of overlapping 15-mers by 10 spanning the entire spike proteins (n = 253). Peptides were synthesized as crude material (TC Peptide lab, San Diego, CA, USA) and resuspended in dimethylsulphoxide. Peptide pools were generated based on spike composition (ancestral or delta), followed by sequential lyophilization steps (Carrasco et al., 2015) . Peptide pools were used at 0.1 µg/mL. Staphylococcal Enterotoxin B (SEB) antigen (Sigma Aldrich) was used at 200 ng/mL.

The spike-specific cellular response was evaluated by the detection of IFN-γ production after stimulation of whole blood with SARS-CoV-2 pools of peptides as previously reported (Petrone et al., 2021a,b,c) . SEB was used as positive control, whereas unstimulated whole blood served as negative control. Briefly, 600 μL of whole blood were overnight stimulated in vitro at 37°C (5% CO2) with spike peptide pools or SEB in a 48-well flat-bottom plate, then, plasma was harvested and stored at -80°C until use. IFN-γ level was measured by an automatic ELISA (ELLA, protein simple) with a detection limit of 0.17 pg/mL. IFN-γ values were subtracted from the negative control value.

The anti-Nucleoprotein IgG (Anti-N IgG) and the anti-RBD IgG (Architect® i2000sr Abbott Diagnostics, Chicago, IL) were evaluated as previously reported (Agrati et al., 2021) . Anti-N IgG are expressed as index whereas anti-RBD IgG are expressed as binding antibody units (BAU)/mL. Anti-N IgG values ≥ 1.4 or anti-RBD IgG ≥ 7.1 were considered positive.

Median and interquartile range (IQR) were reported. The following non-parametric tests were applied: Kruskal-Wallis test for comparisons among groups and Mann-Whitney U-test or Wilcoxon test (for unpaired or paired data, respectively) for pairwise comparisons with Bonferroni correction. Categorical variables were analyzed by the Chi square test. Spearman's Rank test was used to evaluate correlations: r>0.7 indicated a high correlation, 0.7<r>0.5 indicated a moderate correlation and r<0.5 a low correlation. Differences were considered significant if pvalues were <0.05 or <0.008 after Bonferroni correction.

We enrolled 43 IMID patients and 9 immunocompetent subjects. The 97.7% (42/43 subjects) of IMID patients had RA and one patient had pemphigus. All IMID patients were under treatment for their disease. The treatments included methotrexate or other Disease Modifying Anti-Rheumatic Drugs (DMARDs), low dosage of corticosteroids (prednisone <7.5 mg/day or equivalent), biologic drugs and/or combinations of these therapies. IMID patients were stratified according to the therapy regimen. In particular, the following groups were considered: CTLA4-IgG with or without DMARDs or corticosteroids (CTLA4-IgG, n=8 patients); IL-6-inhibitors with or without DMARDs or corticosteroids (aIL-6, n=8 patients); TNF-α-inhibitors with or without DMARDs or corticosteroids (aTNF-α, n=6 patients); DMARDs with or without corticosteroids (DMARD, n=17 patients); Janus Kinases (JAK)-inhibitors with or without DMARDs or corticosteroids (aJAK, n=3 patients) and corticosteroids only The IMID group showed a significant higher median age compared to the immunocompetent subjects (p=0.0006). However, within the IMID group the median age of patients taking different therapies was similar (p=0.165) ( Table 2) .

The demographical and clinical info of the enrolled subjects are described in Table 1 .

We evaluated the IFN-γ-specific response to spike from the ancestral strain and from the δ SARS-CoV-2 variant in IMID patients and in immunocompetent subjects. IFN-γ response to the ancestral peptide pool was slightly lower compared to that observed in response to the δ peptide pool in both IMID patients (ancestral: median 2.03 pg/mL, IQR: 0.11-18.8 pg/mL; delta: median 2.27 pg/mL; IQR: 0.04-12.4) and immunocompetent subjects (ancestral: median 3.89 pg/mL, IQR: 1-79 pg/mL; delta: Figure 1A) .

We stratified IMID patients in four groups according to the drug regimen. We identified six different groups as above reported; however, the aJAK and the corticosteroids groups were excluded from this analysis due to the low number of the subjects included in these groups.

Although not significant, the IFN-γ-specific response to the ancestral or to the δ pools was reduced in subjects under CTLA4-IgG or TNF-α-inhibitors compared to subjects treated with IL-6-inhibitors or DMARDs ( Figure 1B and Supplementary Figure 1B) . In particular, the IFN-γ response to the δ pool in patients under IL-6-inhibitors or DMARDs was higher compared with that observed in subjects taking CTLA4-IgG, although the differences were not significant after applying statistical corrections (p=0.0468 and p=0.022, respectively) (Supplementary Figure 1B) .

We evaluated the vaccine-induced humoral response by measuring the anti-N and anti-RBD IgG levels. All the enrolled subjects scored negative to the anti-N IgG evaluation (Supplementary Figure 2) . Regarding the anti-RBD response, no significant differences were observed between IMID and immunocompetent IgG levels ( Figure 2A) ; moreover, all the immunocompetent subjects scored positive (9/9, 100%), whereas within the IMID group 39/43 (90.7%) subjects had detectable anti-RBD IgG, and 4 subjects were non responders (Table 1) . Stratifying IMID patients based on therapy, no significant differences were observed among the groups analyzed ( Figure 2B) ; however, 2/4 (50%) of non-responders subjects fell in the CTLA4-IgG group ( Figure 2B) .

A low significant correlation was found between the anti-RBD IgG and the IFN-γ levels in response to both the ancestral and the δ spike (ancestral: r s =0.38, p=0.006; δ: r s =0.36, p=0.009) (Supplementary Figure 3) .

The impact of VOCs on the vaccine-induced immune response is of utmost importance, especially in vulnerable populations as patients with IMIDs. We showed that, after vaccination, IMID patients have a similar cellular immune response to the ancestral or δ spike compared to immunocompetent subjects. However, stratifying patients based on the therapy regimen, we observed a trend of reduction of the T-cell specific response in patients taking CTLA4-IgG or TNF-α inhibitors. These results, if confirmed in further studies, may be helpful to guide vaccine strategies and immunosuppressive treatment schedules during vaccination.

Regarding the T cell-specific response, the observed reduction is likely due to the well-known impact of CTLA4-IgG on the down-regulation of the antigen-presentation thus preventing T-cell activation (Bonelli and Scheinecker, 2018) ; on the other side, TNF-α is a key factor in all acute inflammatory reactions, therefore, its inhibition may have broader effects on T-cell responses.

Regarding the antibody response, no significant differences were observed for the anti-RBD IgG response, both quantitative and qualitative, between IMID and immunocompetent subjects. We only found a reduced number of responders in patients under CTLA4-IgG, although it is known that immunosuppressive therapies may have an impact on the antibody response to anti-SARS-CoV-2 vaccines, as recently showed (Picchianti-Diamanti et al., 2021; Connolly et al., 2021; Deepak et al., 2021; Haberman et al., 2021) .

All these findings are relevant in light of new VOCs identification and of co-circulation of different VOCs. In this regard, recently, the T-cell response to spike of the omicron variant has been found in both mRNA-vaccinated subjects at six month from the second dose and in convalescent COVID-19 subjects infected with the ancestral strain, demonstrating that spike-specific CD4+ and CD8+ T cell responses are not weaken by the omicron variant (Gao et al., 2022) . Further studies in vaccinated IMID patients are warranted to confirm these data.

Limitations of the study are related to the low number of subjects evaluated.

However, the IMID patients described here do represent the real clinical scenario of the RA patients under different immune suppressive therapies, and they are homogeneous in terms of age and disease activity. Altogether, these parameters are the premise to generate results leading to reliable considerations. Moreover, the study performed is complete in terms of immune responses evaluated, as both Tand B-cell components were studied.

In conclusion, we demonstrated that cellular responses to δ SARS-CoV-2 variant remain largely intact in IMID. However, the magnitude of these responses may be dependent on the type of immune suppressive regimen. These findings are important to increase our knowledge on the vaccine and to make strategies to halt COVID-19 pandemic.

The authors are grateful to all the patients and nurses who helped to conduct this study. We wish to acknowledge Alessandro Sette for providing peptide reagents.

This work was supported in whole or in part by Federal funds from the National 

A.S. is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress and Repertoire. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work.

None for the other authors. 

Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA

Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients

Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study

How does abatacept really work in rheumatoid arthritis

Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at

Antiviral Therapy, or Both for COVID-19: A Systematic Review

Automatic Generation of Validated Specific Epitope Sets

Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study

SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra

COVID-19 mRNA

Vaccine Immunogenicity in Immunosuppressed Individuals

Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study

Quantitative measurement of infectious virus in SARS-CoV-2 Alpha, Delta and Epsilon variants reveals higher infectivity (viral titer:RNA ratio) in clinical samples containing the Delta and Epsilon variants

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant

The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine

Humoral and cellular response to spike of Delta SARS-CoV-2 variant in vaccinated patients with Multiple Sclerosis

In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy

Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2

ImmunosuppressiveTherapies Differently Modulate Humoral-and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients

Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa

Adaptive immunity to SARS-CoV-2 and COVID-19

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

COVID-19 Weekly Epidemiological Update Edition

WHO announces simple, easy-to-say labels for SARS-CoV-2 Variants of Interest and Concern